Biomerica (BMRA) EBIT (2010 - 2026)

Biomerica has disclosed EBIT across 17 years of filings, most recently posting -$1.3 million for Q1 2026.

• EBIT for Q1 2026 came in at -$1.3 million, down 7.27% year-over-year; the trailing twelve-month figure through Feb 2026 was -$5.4 million (down 312.84% YoY), and the FY2025 annual result was -$5.1 million, down 511.95% from the prior year.
• EBIT came in at -$1.3 million for Q1 2026 at Biomerica, up from -$1.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $6.1 million in Q2 2024 to a low of -$2.1 million in Q3 2022.
• The 5-year median for EBIT is -$1.4 million (2025), against an average of -$986168.8.
• Across the five-year window, EBIT slumped 1435.83% in 2023 and jumped 431.48% in 2024, its largest moves.
• Biomerica's EBIT stood at -$1.7 million in 2022, then rose by 3.48% to -$1.6 million in 2023, then soared by 38.25% to -$993000.0 in 2024, then tumbled by 38.27% to -$1.4 million in 2025, then gained by 5.46% to -$1.3 million in 2026.
• The last three EBIT figures came in at -$1.3 million (Q1 2026), -$1.4 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.